Single-Agent PD-1 Blockade Is "Treatment of Choice" for Desmoplastic Melanoma

Area of Science:

• Oncology
• Dermatology
• Immunotherapy

Background:

• Metastatic desmoplastic melanoma presents a significant clinical challenge with limited treatment options.
• Current treatment guidelines often involve combination therapies, but their efficacy in this specific subtype is under investigation.

Purpose of the Study:

• To evaluate the efficacy of first-line pembrolizumab monotherapy in patients with inoperable metastatic desmoplastic melanoma.
• To compare the response rates of pembrolizumab with existing combination therapies.

Main Methods:

• Phase II clinical trial (S1512) involving patients with inoperable metastatic desmoplastic melanoma.
• Administration of first-line pembrolizumab (anti-PD-1 monotherapy).
• Assessment of patient response rates and outcomes.

Main Results:

• Patients with inoperable metastatic desmoplastic melanoma demonstrated a high response rate to first-line pembrolizumab.
• Pembrolizumab monotherapy proved highly effective in this patient population.

Conclusions:

• First-line pembrolizumab monotherapy is a highly effective treatment for inoperable metastatic desmoplastic melanoma.
• Anti-PD-1 monotherapy should be strongly considered for these patients, potentially offering an alternative to combination regimens like nivolumab-relatlimab.